Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population

References

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9
   PubMed Web of Science ®Google Scholar
• Lin Y, Mousa SS, Elshourbagy N, et al. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins and triglycerides as targets for therapy. Vasc Health Risk Manag 2010;6:73-85
   PubMedGoogle Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates of year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung and Blood Institutes. Circulation 2006;113:2363-72
   PubMed Web of Science ®Google Scholar
• Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-25
   PubMed Web of Science ®Google Scholar
• Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27:1639-46
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health 2010;13:87-94
   PubMed Web of Science ®Google Scholar
• Balu S, Simko RJ, Quimbo RM, et al. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009;25:2765-75
   PubMed Web of Science ®Google Scholar
• Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010;3:CD004371
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• National Quality Forum. National Quality Forum Endorses Measures to Improve Medication Safety and Quality. 2009. Aug 17. Available at: http://www.qualityforum.org/News_And_Resources/Press_Releases/2009/National_Quality_Forum_Endorses_Measures_to_Improve_Medication_Safety_and_Quality.aspx [Last accessed 17 October 2010]
   Google Scholar
• Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10
   PubMed Web of Science ®Google Scholar
• Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10:2973-85
   PubMed Web of Science ®Google Scholar
• Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86
   PubMed Web of Science ®Google Scholar
• Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260-8
   PubMed Web of Science ®Google Scholar
• Sokol M, McGuigan K, Verbrugge R, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GE, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006;12:21-8
   PubMed Web of Science ®Google Scholar
• Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health 2010;64:109-13
   PubMed Web of Science ®Google Scholar
• Albert NM. Improving medication adherence in chronic cardiovascular disease. Crit Care Nurse 2008;28:54-64
   PubMed Web of Science ®Google Scholar
• Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm 2008;14:S2-S10
   PubMed Web of Science ®Google Scholar
• Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:SP11-19
   PubMed Web of Science ®Google Scholar
• Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-12
   PubMed Web of Science ®Google Scholar
• Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009;119:390-7
   PubMed Web of Science ®Google Scholar
• Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-32
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Aslam F, Haque A, Lee V, et al. Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination. Patient Prefer Adherence 2009;3:61-6
   PubMed Web of Science ®Google Scholar
• Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673-81
   PubMedGoogle Scholar
• LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006;40:1274-9
   PubMed Web of Science ®Google Scholar
• Philips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34
   PubMed Web of Science ®Google Scholar
• Lindgren P, Borgström F, Stålhammar J, et al. Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int J Clin Pract 2007;61:1410-14
   PubMed Web of Science ®Google Scholar
• Goldberg KC, Melnyk SD, Simel DL. Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care 2007;13:530-4
   PubMed Web of Science ®Google Scholar